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Abstract: The high incidence of colorectal cancer (CRC) in developed countries indicates a predomi-
nant role of the environment as a causative factor. Natural gut microbiota provides multiple benefits
to humans. Dysbiosis is characterized by an unbalanced microbiota and causes intestinal damage
and inflammation. The latter is a common denominator in many cancers including CRC. Indeed, in
an inflammation scenario, cellular growth is promoted and immune cells release Reactive Oxygen
Species (ROS) and Reactive Nitrogen Species (RNS), which cause DNA damage. Apart from that,
many metabolites from the diet are converted into DNA damaging agents by microbiota and some
bacteria deliver DNA damaging toxins in dysbiosis conditions as well. The interactions between diet,
microbiota, inflammation, and CRC are not the result of a straightforward relationship, but rather a
network of multifactorial interactions that deserve deep consideration, as their consequences are not
yet fully elucidated. In this paper, we will review the influence of dysbiosis in the induction of DNA
damage and CRC.
Keywords: DNA damage; microbiota; nutrition; ROS; bacterial toxins; inflammation
1. Human Microbiota
Microbiota is defined as the group of microorganisms that naturally inhabit the body
of pluricellular organisms. This term includes a highly variable and complex community
of fungi, viruses and bacteria that occupies specific niches in healthy organisms [1,2]. In the
human body, the number of microorganisms is approximately the same as that of human
cells, which is indicative of their significance in human biology [3,4].
Microbiota plays a transcendental role in physiological functions. This community
fulfills metabolic, neuronal and immune requirements including the establishment of
a protective barrier. Nevertheless, in dysbiosis conditions, it is not that the number of
microorganisms may decrease but that the diversity of colonizers changes, with a major
impact on homeostasis. This situation can contribute to the development of autoimmune,
or inflammatory diseases and cancer [4–6].
The term cancer includes a group of diseases characterized by uncontrolled cell
proliferation. Its development depends not only on genetic predisposition but also on
environmental factors. In this particular point, dysbiosis might play important roles in
carcinogenesis and influence their therapy [7–9].
Recently, several studies have reported that a direct secretion of enzymes or molecules
from microbiota can influence the activation of NFKB (nuclear factor kappa-light-chain-
enhancer of activated B cells), apoptosis pathways or cytoskeleton reorganization. More-
over, chemically modified nutrients from diet act as microbiota modulators boosting
ROS/RNS production, toxins and the onset of CRC process [10–12].
Here, we will review the incidence of gut bacterial dysbiosis in CRC development as
well as the mechanisms involved, with special emphasis on those that cause DNA damage.
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2. DNA Damage and Cancer, Old Friends
A well-known feature of cancer cells is genomic instability. Indeed, DNA damage
is responsible for point mutations or chromosome rearrangements frequently found in
transformed cells. Chronic inflammation conditions, as those involved in dysbiosis, may
promote environmental conditions that favor cancer development through induction of
DNA damage [13–15].
DNA can be damaged by endogenous or exogenous sources. Endogenous sources
include ROS/RNS, toxic products from cellular metabolism or disturbances in DNA repli-
cation, i.e., DNA replication–transcription conflicts. On the other hand, ionizing radiation,
UV light and many toxic chemicals used in therapy are exogenous threats to DNA integrity.
DNA Single-Strand Breaks (SSBs) or base damage can be easily found in cells spon-
taneously as a consequence of the action of ROS and RNS. In this sense, a Base Excision
Repair mechanism (BER) can restore the original DNA sequence [13,16]. In the first step
of this process, damaged bases are recognized and excised by DNA glycosylases. Mono-
functional DNA glycosylases such as Uracil DNA Glycosylase (UNG) create only an abasic
site. However, bifunctional glycosylases, such as OGG1, also create a nick on the 3′ side of
the abasic site [16]. The resulting apurinic/apyrimidinic (AP) site or the nicked DNA are
the targets for AP endonuclease (AP-1), which breaks the phosphodiester bond to create
an SSB [16]. Normally Pol β refills the gaps and nicks are resealed by DNA ligase 1 or
ligase 3 [16].
The relationship between BER and Poly (ADP-ribose) polymerase-1 (PARP-1) has
been largely discussed. PARP-1 is reported to be a sensor of SSBs [13,16,17] that arise either
directly or as intermediates of BER [13,16,17]. Indeed SSBs are protected from degradation
by PARP-1 which additionally potentiates the recruitment of repair factors [16]. However,
the involvement of PARP-1 as a member of BER has resulted in controversy over the years.
The Mismatch Repair (MMR) pathway detects and removes DNA base-pair mis-
matches and inappropriate nucleotide insertions/deletions (INDELs) that arise during
DNA replication. There are two important protein complexes involved in MMR, namely
MutS and MutL. MutS has two isoforms; the first (MutSα) is constituted by MSH2 and
MSH6, and the second one (MutSβ) by MSH2 and MSH3. MutL presents three isoforms
namely MutLα (MLH1/PMS2), MutLβ (MLH1/MLH2) and MutLγ (MLH1/MLH3). It
was shown that mutations in one-off MSH2 or MLH1 can affect the entire system [18–20].
Mechanistically, the mismatch is recognized by MutS, then the endonuclease MutL and
the exonuclease EXO1 are recruited. Once resection in the appropriated DNA strand is
finished, polymerase δ and DNA ligase I repair the excised region [21,22].
Microsatellite regions are short sequences of 1 to 6 base pairs, repeated in tandem and
present all through the genome. Due to their nature, they are especially prone to induce
replication errors, which are normally repaired by MMR. In this sense, any inactivating
mutation in the MMR genes mentioned above results in a hyper-mutant phenotype known
as microsatellite instability (MSI), due to a defective MMR system (dMMR) [20,21,23].
Nucleotide Excision Repair (NER) repairs bulky- or helix distorting-DNA lesions.
Depending on how these injuries are detected, NER is classified into Global- (G-NER)
or Transcription-Coupled NER (TC-NER). While G-NER is able to recognize lesions all
through the genome, TC-NER is initiated by the blocking of RNA polymerases by DNA
damage. The subsequent steps are identical in both branches: DNA is then opened, a single-
strand DNA (ssDNA) region of approximately 24–30 base pairs is generated, subsequently
refilled by replication polymerases and ligated by ligase I [24].
The DNA Damage Response (DDR) coordinates the signaling and repair of Double-
Strand Breaks (DSBs) and long stretches of ssDNA with the cell cycle checkpoints [25]. This
is carried out by three phosphoinositide 3-kinase (PI3K)-related serine-threonine kinases,
namely DNA-dependent protein kinase (DNA-PK), ataxia telangiectasia-mutated kinase
(ATM) and ataxia telangiectasia and Rad3-related protein (ATR) [25,26].
ssDNA stretches accumulate when cells suffer replication stress, as intermediates
of the NER pathway and after the resection of DSBs. They are detected by ATR, which
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has a predominant role in phosphorylating and activating CHK1. The resulting ATR-
CHK1 complex mediates various cell responses that include S and G2/M checkpoints that
facilitate DNA repair [27]. Additionally, ATR promotes Homologous Recombination (HR),
regulates proper replication initiation and faithful chromosomal segregation [27,28].
The most difficult DNA lesion to repair is a DSB. One single unrepaired DSB can
induce cell death when essential gene is affected [13]. The MRE11-RAD50-NBS1 (MRN)
complex recognizes the DSB attracting ATM. ATM phosphorylates several proteins that will
mediate cell cycle arrest and DNA repair [25]. In this sense, DNA-PK and H2AX histone
are phosphorylated and hence activated by ATM [29]. Phosphorylated H2AX (γ-H2AX)
will recruit more ATM molecules together with DNA repair factors [25].
DSBs are repaired by two major pathways namely HR and Non-Homologous End
Joining (NHEJ) [25,30,31]. While the former needs the presence of a homologous sequence
(usually a sister chromatid) to faithfully repair a DSB, the latter reseals directly the two bro-
ken edges, which sometimes may put in place new mutations [25,30,31]. As a consequence,
NHEJ is active during all the cell cycles but HR operates mainly during S and G2 phases.
One-ended DSBs are formed by either collision between replication forks and SSBs
or after the processing of stalled forks, and are preferentially repaired by HR. However
two-ended DSBs can be repaired by both systems [30].
A summary of the main DNA repair pathways is depicted in Figure 1.
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3. Colorectal Cancer: The Origin
Although CRC incidence ranks in the third position, and second in terms of mortality
worldwide, only a small percentage is attributable to hereditary factors, most of them
appear in transitioned countries (4-fold higher) and it is due to an inadequate lifestyle [32].
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3.1. The Poisoned Inheritance
Between 2–5% of CRC cases have a hereditary component. The Familiar Adeno-
matous Polyposis (FAP) is present in approximately 1% of CRC cases and is caused by
inherited APC mutations (an early event that facilitates the adenoma–carcinoma transition
via WNT activation) [33,34]. Other examples of CRC-associated inherited mutations are
MUTYH-Associated Polyposis [35], Peutz-Jeghers Syndrome [36] or Serrated Polyposis
Syndrome [36]. Of note, hereditary non-polyposis colorectal cancer (HNPCC), also known
as Lynch Syndrome (LS), is characterized by mutations that inactivate the MMR pathway
and represent 3–4% of all CRC cases [33,34].
Nevertheless, MMR pathway defects are abundant also in sporadic CRC. Indeed,
MLH1 appears inactivated by bi-allelic promoter methylation in 13–16% of sporadic cancers
driving to microsatellite instability (MSI). A defect in MMR has been associated with
mutations in key cellular signaling genes, such as BRAF, that has been linked to the onset
of CRC [20,21,23,37]. Furthermore, a defective MMR was associated with the generation of
neoantigens that promote cell survival against the immune system [20].
In other cases, cancer cells are microsatellite-stable but chromosomally unstable (CIN)
showing mutations in APC, TP53, KRAS, SMAD4, and PIK3CA (around 84% of sporadic
CRC) [20,33,38,39].
3.2. Environment Is the Key
A large number of studies confirm the evidence that environmental factors rather than
inherited genetic dysfunctions operate in the development of most CRC cases [40].
A key event in the development of CRC is the tumourigenic atmosphere caused by
the loss of the epithelium barrier. The breakage of the epithelial layer favors the contact
of bacterial epitopes with immune cells in lamina propria, triggering an exacerbated
immune response that perturbs colon homeostasis [41]. As a result, this proinflammatory
microenvironment promotes the detachment and mobilization of epithelial cells favoring a
dysplasia state [42].
In this aberrant scenario, leukocytes deliver proinflammatory cytokines such as IL-
1β, IL-6 and TNF-α. IL-6 mediates the release of molecules that promote proliferation,
angiogenesis and cell survival [43–45]. IL-1 activates the RAS/MAPK pathway, drives
NFKB downstream genes activation, favors autophagy suppression, tumour cell migration-
invasion and aggressiveness [46–49]. Furthermore, IL-1 was associated with a decrease in
epithelial E-cadherin, which increases the permeability of the epithelial barrier and favors
tumour invasion [50–52].
TNF-α is a key regulator of ROS and RNS signaling. ROS link to several cellular
processes as part of signaling pathways. NFκB regulates genes that modulate the amount
of ROS and, as a feedback loop, ROS might have a stimulatory or inhibitory role in
NFκB signaling [53,54]. In a proinflammatory process, ROS levels might degenerate
into a toxic effect in neighboring cells, exerting a harmful effect on lipids, proteins, and
especially nucleic acids. Long-lasting elevated concentrations of ROS can promote cellular
transformation by inducing DNA damage, cell growth, angiogenesis and metastasis [55,56].
High levels of ROS lead to genetic instability and SSBs because of oxidation of pyrim-
idines and purines and induction of alkali-labile sites [57]. The nucleotide with the high-
est oxidation potential is guanine, giving rise to 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxoG). Incorporated 8-oxoG can be repaired either by BER or MMR, but if it is left
unrepaired C:G > A:T transversion mutations can appear after replication [58]. BER glyco-
sylases involved in the repair of incorporated 8-oxoG are OGG1 (in 8-oxoG:C base pairs)
and MUTYH (in 8-oxoG:A pairs) [16,58]. An excessive number of SSBs, intermediates of
BER and MMR, will induce replication- or transcription-coupled DSBs that will finally end
in chromosome aberrations and cell transformation [58].
Effector immune cells in organs with chronic inflammation release abnormal levels
of nitric oxide (NO), which may alter the physiological function and normal metabolic
state, leading to nitrosation of amines [59]. NO is synthesized by several isoforms, being
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inducible NOS (iNOS), which exhibit greater NO output in immune responses [60]. iNOS
uses NADPH, L-arginine (L-Arg) and oxygen to generate NO and L-citrulline (L-Cit). When
oxygen reacts to the NO surplus produced during the inflammatory process, generates
nitrogen oxides byproducts such as peroxynitrite, N2O3 and N2O4, which are powerful
nitrosating agents [61].
Indeed, RNS converts secondary amines into activated N-nitrosamine intermediates,
which are mutagenic and interact with DNA repair enzymes and transcription factors
such as NFKB (see below) [62,63]. Despite the fact that most endogenous nitrosamines are
produced by the stomach, different studies have shown nitrosamine formation due to amine
production by intestinal bacteria, leading to an increased risk of CRC development [64–66].
Diet-related chronic intestinal inflammation is a proven risk factor for CRC due to
colonization by pathogenic microorganisms, which serve to provide pro-tumour immunity,
exposure of intestinal cells to their mutagenic metabolites and hence potentiate inflamma-
tion. These microorganisms include Colibactin-producing Escherichia coli, enterotoxigenic
Bacteroides fragilis and Helicobacter hepaticus among others [67].
It was recently reported that tissue damage or, chronic inflammation induced by such
bacteria species, induce oxidative stress and hence 8-oxoG and DSBs [58]. Furthermore,
antioxidants such as vitamin C are able to reduce DNA damage and tumourigenesis in this
context [58]. In a mouse model for LS, 8-oxoG and DSB resulted higher in MMR defective
animals, but antioxidants failed to prevent tumourigenesis [58].
In the next points, we will review more environmental factors involved in CRC
development under a DNA damage perspective, such as microbiota-modified metabolites
from diet or bacterial toxins.
4. DNA Damage Induced by Metabolites from Diet
Nutritional habits seem to modulate microbiota diversity and hence influence col-
orectal tumourigenesis [68–70]. Healthy diets such as vegan, Mediterranean, or Japanese
diets have demonstrated protection against the development of several cancers, besides
a reduction in fatality associated with them [71]. It is well accepted that high fiber food
protects against CRC, on the other hand, high amounts of red meat, saturated fat and
processed food favor its development [40,72–74]. Some bacterial strains present in healthy
microbiota are Bacteroidetes (Gram-negative) and Firmicutes (Gram-positive) with lower
amounts of Actinobacteria and Verrumicrobia [75]. In contrast, certain strains of Bacteroides
fragilis and Escherichia coli (carrying PKs islands), Streptococcus gallolyticus, Enterococcus
faecalis and Fusobacterium nucleatum are abundant in CRC patients [49,67,76].
Most nutrients are absorbed in the small intestine; nevertheless, complex carbohy-
drates, protein-derived compounds and bile acids might reach the large intestine [40]. Once
there, microbiota metabolizes those compounds giving rise to “oncometabolites” and “tu-
mour suppressor metabolites” with immune, epigenetic and genotoxic consequences [72].
The proposed mechanisms for these compounds are summarized in Figure 2.
4.1. Metabolites from Carbohydrates
Butyrate, propionate and acetate are short-chain fatty acids (SCFA) that result from
dietary fiber fermentation by microbiota [77]. These compounds may suppress tumour
development through several mechanisms [40]. The main SCFA producers are Bacteroidetes,
Clostridium, Eubacteria and Roseburia [40,74,78], which were found to be diminished in CRC
patients [78].
The importance of butyrate in the intestinal epithelium is well documented [40,77].
Butyrate is the main energy source for enterocytes, increases mucin production and induces
the protein expression of claudins and occludines, which participate in the epithelial
barrier [77]. Epithelial impermeability is important to avoid the translocation of bacteria or
their metabolites to lamina propria, preventing inflammatory episodes.
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In a healthy colon, butyrate induces cell proliferation due to its role as an energy supplier
but also decreases cancer risk through epigenetic regulation [40]. Here, butyrate is metabolized
into acetyl-CoA, which stimulates histone acetyltransferase (HAT) activity [79].
On the other hand, CRC is characterized by a high protein expression of HDAC
(Histone deacetylase) [40,80], which drives cells to profound epigenetic changes [80].
Due to the Warburg effect, transformed cells prefer glucose to butyrate as energy source.
Subsequently, there is an accumulation of butyrate in neoplastic epithelium, which triggers
apoptosis via HDAC inhibition [40,73,79].
4.2. Metabolites from Fat and Bile Acids
Bile acids are secreted into the small intestine from the gallbladder where they emulsify
dietary fats [81]. Primary bile acids such as cholic and chenodeoxycholic, are synthesized
by the liver from cholesterol and conjugated with glycine or taurine which increases its
emulsifying properties [81].
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Most of the bile acids are recycled into the enterohepatic circulation. Nevertheless, a
residual fraction may remain in the large intestine where it is converted by Bacteroides and
Bilophilia into secondary bile acids such as deoxycholic and lithocholic [82].
Deoxycholic and lithocholic cause ROS and membrane damage in enterocytes. Subse-
quently, arachidonic acid is released and converted by Lipoxygenase (LOX) and Cycloxyge-
nase 2 (COX-2) enzymes into inflammatory prostaglandines and ROS overproduction [9].
Furthermore, secondary bile acids have an inhibitory effect on DNA repair systems,
leading to an increment of mutated cells with a marked genetic instability, characterized by
the induction of SSB, DSB and aneuploidy [82,83]. DNA repair systems downregulated
by secondary bile acids are HR, NER, NHEJ and MMR. Furthermore, levels of ATM are
reduced as well as OGG1 and MUTYH glycosylases [82,83].
Additionally, it was reported that deoxycholic acid induces proteasomal degradation
of p53 [84] and activates survival and proliferative pathways such as Wnt/β-catenin [83],
PKC [85] and NFKB [85], which egress apoptosis-resistant clones [82,83].
4.3. Metabolites from Proteins
Protein degradation by colon microbiota has been extensively studied [40,81,86].
Colon bacteria break down undigested peptides, digestive enzymes, mucin and cell debris
from the small intestine [40,81,86]. As a result, fatty acids, short peptides and amino acids
are generated. However, many toxic compounds are also released such as amines, nitrates,
nitrites, N-nitrosamines, hydrogen sulfide (H2S), p-cresol and ammonia [40]. Protein
fermentation by microbiota is higher at the distal part of the large intestine, where these
metabolites are found at larger concentrations [86,87].
4.3.1. p-Cresol
When aromatic amino acids, such as tyrosine, tryptophan and phenylalanine ferment,
a wide variety of phenolic and indolic compounds are generated. For instance, tyrosine
fermentation generates p-cresol reaching up to 0.5 mM concentration in human feces [87,88].
Most of the p-cresol is absorbed by enterocytes and later on, metabolized by the liver and
excreted in urine [86,87].
Andriamihaja and colleagues studied the deleterious effects of millimolar concentra-
tions of p-cresol on the human adenocarcinoma cell line HT-29 Glc −/+ [87]. They found
that p-cresol at 0.8 mM diminished cell proliferation due to an increase in cell detachment
and S-phase delay [87]. Potentially, this detachment could implicate the disruption of the
epithelial barrier in vivo and causes colon inflammation. P-cresol concentrations above
1.6 mM were genotoxic as measured by the γ-H2AX foci assay. Additionally, p-cresol had a
negative effect on the mitochondrial respiratory chain with subsequent anion superoxide
(ROS) production. According to the authors, the observed toxicity is independent of DNA
damage induction [87].
Recently, a report strengthens the hypothesis that colon microbiota-derived p-cresol
behaves as a genotoxic agent at physiological concentrations [75]. Bacterial cultures from
human fecal inoculums were grown with a high tyrosine supplement and supernatants
were used to treat HT29 and Caco-2 cells for 24 h. According to the data, p-cresol could
serve as a great predictor of genotoxicity in enterocytes. Cell cycle was arrested in S phase
at 0.5 mM, however, this effect was not evident at higher concentrations [75]. Authors
explain that low doses of p-cresol induce tumour growth [89], though; this effect is masked
at higher concentrations by DNA damage-induced G0/G1 and G2/M checkpoints [75].
4.3.2. H2S
Another important residual metabolite from sulfate-reducing bacteria is H2S [40,81,90].
Classically this molecule was considered as a toxic molecule, although in recent decades,
it is believed that H2S behaves as a signaling molecule in physiological processes such as
cell proliferation, apoptosis, inflammation, hypoxia, neuromodulation and cardioprotec-
tion [91]. In mammals, the production of H2S results from the enzymatic action of cys-
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tathionine beta-synthase (CBS), cystathionine gamma-lyase (CSE) and 3-mercaptopyruvate
sulfurtransferase (3-MST) [91].
Regarding to CRC, H2S has been described to have pro- and anticancer effects. En-
dogenously produced H2S or low H2S treatments can maintain or promote cancer growth
while high exposures exhibit anticancer effects [92]. Endogenously CBS-produced H2S
can promote angiogenesis and maintain cellular bioenergy in colon cancer cells [92]. Fur-
thermore, at 24 h of exogenous exposure to 50–200 µM of NaHS (a donor of H2S), can
accelerate cell cycle progression by decreasing the levels of p21 and increasing the levels of
S phase cells [92,93]. However, relatively high concentrations of exogenous H2S can have a
growth-suppressive effect. For instance, 1 mM of NaHS for 12–24 h upregulates the protein
expression of p21 in human colon cancer cells [92,94].
Another main issue is autophagy. Autophagy is a catabolic process that involves the
lysosomal digestion and subsequent recycling of internal components [95]. Concerning
cancer progression, autophagy has a dual role. Initially, in pre-malignant lesions, autophagy
prevents cancer development but if cancer is well-established, autophagy facilitates tumour
survival and growth [95]. Recently, it was shown that endogenous levels or exogenous
treatments with H2S in several hepatocarcinoma cell lines could present opposite effects on
autophagy [96].
In reference to DNA damage induction, H2S was reported to be genotoxic for ente-
rocytes and has been associated with ulcerative colitis and CRC [40,81,90,97,98]. H2S, at
doses found in human colon (250 µM), induced DNA damage to CHO cells [97]. Similar
data was found when the HT29-Cl.16E colon cell line was assayed with higher H2S con-
centrations [97]. In this case a modified alkaline comet assay, in which DNA repair was
inhibited by hydroxyurea and a chain terminator (Ara-C) was used [99]. Taken together, a
DNA repair defect and the presence of H2S arguably predispose enterocytes to genomic
instability in a cancer progression context [97].
Later on, it was reported that H2S induced-DNA damage was based on a free radicals
production mechanism [98]. The exposure to H2S rapidly increased the NADPH/NADP
ratio through inhibition of mitochondrial respiratory chain in the non-transformed rat
intestinal cell line IEC-18 [100,101]. The electron transport chain defect observed could be
responsible for the generation of genotoxic free radicals.
Additionally, it was found that H2S induced DNA damage in a colon non-transformed
human cell line (FHs 74 Int) at doses that can be found in large intestine [90]. Doses lower
than 500 µM were genotoxic and induced changes in gene expression patterns without
showing cytotoxic effects. Indeed, pro-inflammatory COX-2 expression was approximately
8-fold upregulated after 30 min exposure [90]. The expression of several genes related
to the DNA damage response was also altered. For instance, GTF2H1, belonging to
multimeric transcription factor II H (TFIIH), which is involved in NER, and XRCC6, linked
to NHEJ were upregulated within the first 30 min. However, RAD51 (HR) and MLH1 were
downregulated after 4 h exposure [90].
A high protein expression of COX-2 was linked to transformed epithelial cells and acti-
vated macrophages in CRC [102,103]. Activation of the NFKB pathway and the subsequent
synthesis of proinflammatory cytokines has also been reported in monocytes exposed to
H2S [104].
In 2019, Chen and coworkers showed how H2S regulates ATR levels and its phospho-
rylation [28]. The presented data show how ATR orchestrates the DDR induced by H2S.
Indeed, cells carrying ATR mutations showed DNA damage after low H2S exposure, and
were hypersensitive to higher concentrations [28]. However, a complex regulatory mecha-
nism between ATR and H2S was postulated [28]. First, ATR inversely regulates enzymes
involved in H2S synthesis and hence H2S concentration. Second, high H2S concentrations
suppress ATR phosphorylation at serine 435 (ATR-pS435) while low levels increase it [28].
Of interest, PKA-mediated ATR phosphorylation at serine 435 is required to promote NER
and reduces mutagenesis via ATR-XPA complex formation [105].
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4.3.3. N-Nitrosamines
N-nitrosamines are organic molecules derived from protein fermentation. These
compounds result from the combination of amines and nitrates. N-nitrosomorpholine,
N-nitrosodimethylamine and N-nitrosopyrrolidine are the most relevant compounds in
this group [40].
N-nitrosamines require metabolic activation by cytochrome P450 to wield their car-
cinogenic effect [106,107]. Then, nitrosamines are α- and β-hydroxylated giving rise to
end products that can finally alkylate nucleophilic sites of DNA. Consequently, mutagenic
alkali-labile adducts are generated, leading to abasic site formation and DNA strand breaks
that can be detected by alkaline comet assay [106–108].
Moreover, it was previously reported that N-nitrosamines induce free radicals and
therefore oxidized bases [106–110]. In this context, it was demonstrated in vitro that
neutrophil activation may generate carcinogenic nitrosamines [65].
4.3.4. Ammonia
To our knowledge, there are no reports that deepen in the analysis of DNA damage in
enterocytes exposed to high ammonia concentrations. Ammonia caused p53 activation,
p21 upregulation, mitochondrial dysfunction, ROS generation, DNA damage and cellular
senescence in astrocytes, neurons and hepatic endothelial cells from hepatic encephalopa-
thy patients [111,112]. In epithelial cells from mammary bovine glands, high ammonia
concentrations gave rise to the same effects described above [113].
High ammonia concentrations reduce the absorptive capacity and survival rate of the
enterocytes. This scenario promotes mucosal turnover, inflammation and fragility of the
epithelial intestinal barrier [86].
4.4. Phytochemicals and Vitamins
Phytochemicals are micronutrients synthesized by plants and abundant in fruit, veg-
etables, legumes, tea or wine, highly beneficial to human health [114]. Due to their com-
plexity, 95% of phytochemicals are absorbed and transformed into more active secondary
metabolites by colon microbiota [115]. For instance, soy isoflavones such as daidzein or
genistein can be differentially metabolized by microbiota giving alternative secondary
metabolites [116,117].
Flavonoids are the largest group of phytochemicals. This group includes isoflavones,
anthocyanins and catechins between others.
The anticancer properties of isoflavones and their derivatives have been extensively
studied. They are anti-inflammatory and antioxidant molecules that interfere in several cell
signaling pathways such as NFKB, AKT or MAPK/ERK, inhibiting cancer growth [117,118].
Anthocyanins are flavonoids with anti-inflammatory, anti-oxidative and anti-cancer
properties [119–121]. They modulate bacteria involved in CRC development, by inhibiting
the propagation of Helicobacter pylori or promoting the growth of Bifidobacterium spp. and
Lactobacillus-Enterococus spp. [122]. Additionally, these compounds are able to modulate the
oxidative stress by blocking the phosphorylation of NFKB, which is one of the main causes
of DNA damage, and downregulating TNFα, COX2 and iNOS mRNA expression [123].
Flavonoids commonly named catechins are antioxidants and anti-inflammatory molecules.
The underlying mechanisms comprise the inhibition of ROS, hypoxia and NFKB signaling
cascades. In addition, catechins modulate COX2, block of the epidermal growth factor re-
ceptor (EGFR) and insulin-like growth factor receptor-1 (IGFR-1) signaling pathways [124].
Green tea catechins modify gut microbiota composition and protect against CRC. An
elevated number of bacterial SCFA-producing strains, reduced Fusobacterium spp. and
increased FIR/BAC (Firmicutes to Bacteroidetes ratio) ratio were reported [125]. Never-
theless, if catechins concentration is high enough, they behave as pro-oxidant elements
generating ROS, DNA damage as well as MMPs production. Furthermore, inhibition of
Topoisomerases I and II, which induce DNA damage, have been reported [126,127]. Indeed,
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catechins, in a dose-dependent manner, increase the yield of endoreduplicated cells, a
topoisomerase II dysfunction marker [128].
Vitamins are essential organic elements for proper homeostasis. It is widely known
that colon microbiota plays an important role in vitamin acquisition. Some bacteria strains
can synthesize vitamins of K and B groups establishing another vitamin absorption source.
Dysbiosis changes microbiota diversity and hence vitamin acquisition by colon may result
altered [81].
Low levels of folate (vitamin B9) were associated with different types of cancer (colon,
lungs, breast, brain, etc.) in adults, as well as cognitive deficiencies in babies. The underly-
ing mechanism involved is linked to DNA synthesis, repair, and methylation. S-adenosyl
methionine (SAM) donates methyl groups to DNA methyltransferases (DNMTs) and com-
plete the DNA methylation process. When folate levels are low, SAM concentration is
reduced, leading to DNA hypomethylation that links to proto-oncogenes mRNA expres-
sion [129].
Moreover, low folate conditions alter the purine-pyrimidine balance, giving rise to
collapsed replication forks and hence one-ended DSBs [130]. Besides, vitamin B9 deficiency
inhibits the methylation of dUMP to dTMP, which causes massive uracil incorporation into
DNA. BER could result overwhelmed and then high amounts of SSBs and chromosomal
breaks are generated [131].
Niacin or vitamin B3 is the precursor of nicotinamide adenine dinucleotide (NAD)
and nicotinamide adenine dinucleotide phosphate (NADP). These coenzymes are cofactors
in almost all metabolic processes, regulating PARP and sirtuins, among others, which are
relevant for genetic and epigenetic regulation [132].
A deficiency in niacin unbalances the NAD+/NADH ratio disrupting a large number
of processes including DNA repair. Genetic instability and increased risk of cancer devel-
opment are frequently associated with low levels of niacin, as PARP requires the presence
of NAD+ to efficiently repair DNA damage [132].
5. Microbiota Genotoxins
Dysbiosis conditions and perturbed microbiota may include pathogenic strains that
synthesize DNA damaging toxins (Figure 3) [133].
5.1. Colibactin
Colibactin is a genotoxic compound produced by some E. coli strains that can induce
DSB, chromosomal aberrations and G2/M cell cycle arrest [134].
Three non-ribosomal peptide megasynthases, three polyketide megasynthases, two
hybrid megasynthases and some accessory proteins are responsible for Colibactin synthesis
as a propeptide [134]. To become active, the propeptide is processed by an inner-membrane-
bound peptidase called Colibactin peptidase (ClbP) that cleaves acyl asparagine residues
located in the N-terminus [135].
Active Colibactin can form interstrand cross-links (ICL) with DNA. These structures
block replication forks and are processed into one-ended DSB via Fanconi Anemia Repair
Pathway (FA) and finally repaired by HR (Figure 1). Indeed, Bossuet-Greif and coworkers
found that γ-H2AX foci (a DSB marker) colocalized with FANCD2 (a FA marker) foci after
Colibactin exposure [136]. In agreement with that, Colibactin induced an ATR-mediated
replication stress response [136].
NHEJ deficient cells resulted hypersensitive to Colibactin, so apparently, two-ended
DSB might be induced [137]. Herzon et al. deciphered more about the nature of Colibactin-
induced DNA damage. They concluded that Colibactin induces N3-Adenine alkylations
that are depurinated by BER into AP sites, promoting a SSB in each DNA strand and finally
DSBs are formed [15,138,139].




Figure 3. Bacterial toxins induce a high variety of DNA lesions in colon epithelium. A hallmark of colon dysbiosis is the 
growth of pathogenic bacteria that release toxins that induce DNA damage. Toxins depicted here can damage host DNA 
through different mechanisms, such as induction of interstrand crosslinks (ICL), generation of ROS, DNA alkylation or 
inhibiting MMR. EPEC: Enteropathogenic E. coli toxin, CdtB: Cytolethal distending toxin, BFT: Bacteroides fragilis toxin, 
Fn: Fusobacterium nucleatum toxins, TV: tilivalline, TM: tilimycin, MMR: mismatch repair system, dMMR: defective mis-
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5.1. Colibactin 
Colibactin is a genotoxic compound produced by some E. coli strains that can induce 
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Three non-ribosomal peptide megasynthases, three polyketide megasynthases, two 
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Figure 3. Bacterial toxins induce a high variety of DNA lesions in colon epithelium. A hallmark of colon dysbiosis is the
growth of pathogenic bacteria that release toxins that induce DNA damage. Toxins depicted here can damage host DNA
through different mechanisms, such as induction of interstrand crosslinks (ICL), generation of ROS, DNA alkylation or
inhibiting MMR. EPEC: Enteropathogenic E. coli toxin, Cd B: C tolethal distending toxin, BFT: Bacteroides fragilis toxin, Fn:
Fusobacterium nucleatum toxins, TV: tilivalline, TM: tilimycin, MMR: mismatch repair system, dMMR: defective mismatch
repair, MSI: microsatellite instability, DSB: double strand break.
This genotoxin prom tes lon t mour growth by inducing a senescent cell phenotype
that se retes growth factors. The mechanism is based on an up-regulation of c-MYC
protein lev ls after DNA-damage induction. c-MYC increases microRNA-20a-5p expression
that blocks SENP1 mRNA translation [140]. Thi situation triggers an accumula ion of
sumoylated-P53. Therefore, the transcriptional activating function and DNA binding
capacity of P53 will be abrogated [141]. Most likely sumoylated P53 enhances a senescent
cellular state [142].
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5.2. Toxins Generated by EPEC
Enteropathogenic E. coli (EPEC) can settle in the host’s gut epithelium through close
interaction with intimin adhesion protein and disrupts MMR [143,144].
EPEC effector proteins may cause increased host mutations by depleting the MLH1
and MSH2 protein pool while their transcription is enhanced [145]. The underlying mecha-
nism is mediated by ROS production and could disrupt MLH1 and MSH2 heterodimers
formation. This mechanism is not enough to inhibit MMR completely, but Map and EspF
proteins can totally block MSH2 [145,146]. MMR dysfunction increases spontaneous muta-
tions that can affect tumour suppressor genes. This could explain the axis between chronic
EPEC infections and CRC [144,146].
5.3. Cytolethal Distending Toxins (Cdt)
Cdt are a family of cytotoxins produced by different bacterial strains including He-
licobacter hepaticus, whose Cdt has a key role in carcinogenesis [147,148]. Some of these
genotoxins can induce DBSs and G2/M cell cycle arrest [149–151]. The common structure
comprises three subunits: a catalytic CdtB and two lectin-like subunits, which mediate host
cell membrane adhesion and invasion [149].
CdtB exhibits PI-3,4,5-triphosphate phosphatase activity and DNase I-like structure
and activity. These functions may explain its capacity to induce DSB and cell cycle arrest.
Rapamycin alleviates CdtB genotoxicity, so its mechanism of action might be mediated by
mTOR [148,149].
These toxins could also affect host gene expression and microbiota composition. Some
studies have found an up-regulation of two carcinogenic pathways: peroxisome proliferator-
activated receptors (PPAR) signaling pathway and calcium signaling pathway [148].
5.4. Bacteroides Fragilis Toxin (BFT)
BFT is a metalloprotease produced by Enterotoxigenic B. fragilis. The long-term
presence of these bacteria, and therefore of BFT, may be related to the pathogenesis of
familiar adenomatous polyposis (FAP) contributing to CRC development [152].
BFT is synthesized as a propeptide and processed into its active form before secretion.
Once inside target cells, BFT promotes E-cadherins cleavage, stress response activation,
cytokine secretion and increased proliferation [153,154].
E-cadherins degradation could be mediated by an unknown BFT surface protein
receptor instead of BFT direct action as a metalloprotease [154]. Up-regulation of spermine
oxidase (SMO) and the induction of cIAP2 (an antiapoptotic protein) may be some addi-
tional mechanisms. SMO is an inflammatory-inducible polyamine catabolic enzyme that
promotes the generation of ROS and the induction of DNA damage [153].
5.5. Fusobacterium Nucleatum (Fn) Toxins
Fusobacterium nucleatum (Fn) is an anaerobic Gram-negative bacteria frequently found
in CRC patients’ microbiota. There is a correlation between Fn infections with genetic and
epigenetic changes related to poor CRC prognosis [155].
Fn adheres cell surface in order to invade and induce its oncogenic and inflammatory
effects. FadA is a protein produced by Fn that binds to an 11-amino-acid region of the cell’s
E-cadherin and promotes Fn attachment and invasion [156].
The mechanism underlying Fn oncogenic process may be mediated by ROS and
pro-inflammatory factors. ROS could be responsible for the hypermethylation of CpG
promoter islands and non-promoter hypomethylation of CpG regions leading to microsatel-
lite instability and other epigenetic changes. Simultaneously, ROS and pro-inflammatory
factors may induce DNA damage [155]. FadA could also contribute to inflammation via
the β-catenin pathway [156].
Furthermore, Fn may disrupt NHEJ repair by downregulating KU70, a protein re-
quired to start the NHEJ process, while inducing DSB. Finally, the capacity to downregulate
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P27, a cyclin-dependent kinase inhibitor, increases cell proliferation and causes cell cycle
arrest in S phase [157].
5.6. Klebsiella Oxytoca Enterotoxins
Antibiotic-associated hemorrhagic colitis (AAHC) is a disease caused by the expansion
of colitogenic strains of Klebsiella oxytoca in some patients after antibiotics such as penicillin
treatment [158]. Recently biofilms of K. oxytoca were identified in patients with CRC [159].
These bacteria present a gene cluster that encodes a non-ribosomal peptide assembly
pathway that produces three secondary metabolites. Two of these metabolites, tilimycin
(TM) and tilivalline (TV), present cytotoxic activity. The enzymes encoded by the gene clus-
ter synthesize TV directly while TM requires the reaction between an imine intermediate
metabolite of TV with indole [160].
TV is unable to bind to DNA or behave like a genotoxic agent by itself. TV induces
microtubule-stabilization targeting tubulin and promoting tubulin-GTP state. This stabiliza-
tion leads to a G2/M cell cycle arrest that is frequently resolved through multipolar anaphases.
On the other hand, TM binds to and alkylates DNA directly. These lesions trigger
a DDR in the host that could lead to the formation of adducts SSBs or DSB after the
intervention of repair systems, arresting cells in G1 or S phase. Cells without Cockayne
Syndrome group B protein (CSB), Cockayne Syndrome group A protein (CSA) and/or
NER XPA resulted hypersensitive to TM, which could be explained by an essential role of
TC-NER in the repair of TM induced-DNA lesions [160].
Both toxins may impair the intestinal barrier through two different mechanisms:
increasing epithelial apoptosis and decreasing the expression of claudin-5 and claudin-8
proteins, contributing to tumour invasion and development [161].
6. Conclusions
The relationship between healthy habits, including diet and cancer, has been exhaus-
tively researched. In this review, we envisioned this complex system emphasizing the
direct or indirect roles of microbiota in DNA damage induction.
The diet and microbiota axis seems to be an indivisible factor. Microbiome’s metabo-
lites may act as pro or anti-carcinogenic compounds depending on diet that in turn acts
by remodeling microbiota composition itself. In this context, normal microbiota protects
the epithelium barrier against harmful bacteria, inflammation, and DNA damage while
diet-induced dysbiosis may lead to the opposite effects.
In conclusion, a greater understanding of DNA damage pathways induced by a diet-
modified microbiota may lead to new approaches and treatments to decrease the risk of
CRC development.
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